Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have described indazole macrocycles acting as stimulator of interferon genes protein (STING; TMEM173) antagonists reported to be useful for the treatment of cancer, autoimmune diseases, inflammatory, neurological, metabolic, cardiovascular and eye disorders.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have identified haloindole macrocyclic compounds acting as GTPase KRAS (G12C mutant) inhibitors and thus reported to be useful for the treatment of cancer.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have patented new NLRP3 inflammasome inhibitors reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease, Parkinson’s and Alzheimer’s diseases.
An F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. patent describes indole derivatives acting as EGFR L858R mutant, T790M/L858R double mutant, T790M/L858R/C797S triple mutant and/or L858R/C797S double mutant allosteric inhibitors reported to be useful for the treatment of non-small-cell lung cancer (NSCLC).
Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have synthesized radiolabeled compounds acting as GABA(A) receptor subunit α2β2γ1 (GABRA2) positive allosteric modulators acting as positron-emission tomography (PET) and autoradiography imaging agents reported to be useful for the diagnosis of neurological disorders.
Researchers from F. Hoffmann-La Roche Ltd., Hoffmann-La Roche Inc. and Icagen Inc. have disclosed heteroaryl-urea compounds acting as potassium voltage-gated channel subfamily KQT member 2 (KCNQ2; Kv7.2) activators reported to be useful for the treatment of autism spectrum...
Researchers from F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have synthesized NLRP3 inflammasome inhibitors reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease, Parkinson’s disease and Alzheimer’s disease.
